[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models.

Lubet, Ronald A; Steele, Vernon E; Juliana, M M; Bode, Ann; Moeinpour, Fariba; Grubbs, Clinton J.

Afiliação

Lubet RA; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA.
Steele VE; Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA.
Juliana MM; Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Bode A; Division of Cancer Biomarkers and Drug Resistance, University of Minnesota Hormel Institute, Austin, MN 55912, USA.
Moeinpour F; Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Grubbs CJ; Department of Surgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Oncol Rep ; 41(1): 718, 2019 01.

Article em En | MEDLINE | ID: mdl-30365076

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article